201 related articles for article (PubMed ID: 25549870)
1. Evaluation of the interindividual human variation in bioactivation of methyleugenol using physiologically based kinetic modeling and Monte Carlo simulations.
Al-Subeihi AA; Alhusainy W; Kiwamoto R; Spenkelink B; van Bladeren PJ; Rietjens IM; Punt A
Toxicol Appl Pharmacol; 2015 Mar; 283(2):117-26. PubMed ID: 25549870
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of human interindividual variation in bioactivation of estragole using physiologically based biokinetic modeling.
Punt A; Jeurissen SM; Boersma MG; Delatour T; Scholz G; Schilter B; van Bladeren PJ; Rietjens IM
Toxicol Sci; 2010 Feb; 113(2):337-48. PubMed ID: 19920071
[TBL] [Abstract][Full Text] [Related]
3. Development of a Combined In Vitro Physiologically Based Kinetic (PBK) and Monte Carlo Modelling Approach to Predict Interindividual Human Variation in Phenol-Induced Developmental Toxicity.
Strikwold M; Spenkelink B; Woutersen RA; Rietjens IMCM; Punt A
Toxicol Sci; 2017 Jun; 157(2):365-376. PubMed ID: 28498972
[TBL] [Abstract][Full Text] [Related]
4. Human cytochrome p450 enzymes of importance for the bioactivation of methyleugenol to the proximate carcinogen 1'-hydroxymethyleugenol.
Jeurissen SM; Bogaards JJ; Boersma MG; ter Horst JP; Awad HM; Fiamegos YC; van Beek TA; Alink GM; Sudhölter EJ; Cnubben NH; Rietjens IM
Chem Res Toxicol; 2006 Jan; 19(1):111-6. PubMed ID: 16411663
[TBL] [Abstract][Full Text] [Related]
5. Physiologically based biokinetic model of bioactivation and detoxification of the alkenylbenzene methyleugenol in rat.
Al-Subeihi AA; Spenkelink B; Rachmawati N; Boersma MG; Punt A; Vervoort J; van Bladeren PJ; Rietjens IM
Toxicol In Vitro; 2011 Feb; 25(1):267-85. PubMed ID: 20828604
[TBL] [Abstract][Full Text] [Related]
6. Physiologically based kinetic modeling of bioactivation and detoxification of the alkenylbenzene methyleugenol in human as compared with rat.
Al-Subeihi AA; Spenkelink B; Punt A; Boersma MG; van Bladeren PJ; Rietjens IM
Toxicol Appl Pharmacol; 2012 May; 260(3):271-84. PubMed ID: 22445790
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of methyleugenol bioactivation by the herb-based constituent nevadensin and prediction of possible in vivo consequences using physiologically based kinetic modeling.
Al-Subeihi AA; Alhusainy W; Paini A; Punt A; Vervoort J; van Bladeren PJ; Rietjens IM
Food Chem Toxicol; 2013 Sep; 59():564-71. PubMed ID: 23831728
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Interindividual Human Variation in Bioactivation and DNA Adduct Formation of Estragole in Liver Predicted by Physiologically Based Kinetic/Dynamic and Monte Carlo Modeling.
Punt A; Paini A; Spenkelink A; Scholz G; Schilter B; van Bladeren PJ; Rietjens IM
Chem Res Toxicol; 2016 Apr; 29(4):659-68. PubMed ID: 26952143
[TBL] [Abstract][Full Text] [Related]
9. Inter-individual variation in chlorpyrifos toxicokinetics characterized by physiologically based kinetic (PBK) and Monte Carlo simulation comparing human liver microsome and Supersome
Zhao S; Wesseling S; Rietjens IMCM; Strikwold M
Arch Toxicol; 2022 May; 96(5):1387-1409. PubMed ID: 35294598
[TBL] [Abstract][Full Text] [Related]
10. Integrating physiologically based kinetic (PBK) and Monte Carlo modelling to predict inter-individual and inter-ethnic variation in bioactivation and liver toxicity of lasiocarpine.
Ning J; Rietjens IMCM; Strikwold M
Arch Toxicol; 2019 Oct; 93(10):2943-2960. PubMed ID: 31511935
[TBL] [Abstract][Full Text] [Related]
11. A comparative in vitro kinetic study of [14C]-eugenol and [14C]-methyleugenol activation and detoxification in human, mouse, and rat liver and lung fractions.
Minet EF; Daniela G; Meredith C; Massey ED
Xenobiotica; 2012 May; 42(5):429-41. PubMed ID: 22188410
[TBL] [Abstract][Full Text] [Related]
12. Physiologically based biokinetic (PBBK) model for safrole bioactivation and detoxification in rats.
Martati E; Boersma MG; Spenkelink A; Khadka DB; Punt A; Vervoort J; van Bladeren PJ; Rietjens IM
Chem Res Toxicol; 2011 Jun; 24(6):818-34. PubMed ID: 21446753
[TBL] [Abstract][Full Text] [Related]
13. Human cytochrome p450 enzyme specificity for the bioactivation of estragole and related alkenylbenzenes.
Jeurissen SM; Punt A; Boersma MG; Bogaards JJ; Fiamegos YC; Schilter B; van Bladeren PJ; Cnubben NH; Rietjens IM
Chem Res Toxicol; 2007 May; 20(5):798-806. PubMed ID: 17407329
[TBL] [Abstract][Full Text] [Related]
14. Physiologically based biokinetic (PBBK) modeling of safrole bioactivation and detoxification in humans as compared with rats.
Martati E; Boersma MG; Spenkelink A; Khadka DB; van Bladeren PJ; Rietjens IM; Punt A
Toxicol Sci; 2012 Aug; 128(2):301-16. PubMed ID: 22588462
[TBL] [Abstract][Full Text] [Related]
15. A physiologically based in silico model for trans-2-hexenal detoxification and DNA adduct formation in human including interindividual variation indicates efficient detoxification and a negligible genotoxicity risk.
Kiwamoto R; Spenkelink A; Rietjens IM; Punt A
Arch Toxicol; 2013 Sep; 87(9):1725-37. PubMed ID: 23864024
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the human kinetic adjustment factor for the health risk assessment of environmental contaminants.
Valcke M; Krishnan K
J Appl Toxicol; 2014 Mar; 34(3):227-40. PubMed ID: 24038072
[TBL] [Abstract][Full Text] [Related]
17. Physiologically based kinetic models for the alkenylbenzene elemicin in rat and human and possible implications for risk assessment.
van den Berg SJ; Punt A; Soffers AE; Vervoort J; Ngeleja S; Spenkelink B; Rietjens IM
Chem Res Toxicol; 2012 Nov; 25(11):2352-67. PubMed ID: 22992039
[TBL] [Abstract][Full Text] [Related]
18. Study on inter-ethnic human differences in bioactivation and detoxification of estragole using physiologically based kinetic modeling.
Ning J; Louisse J; Spenkelink B; Wesseling S; Rietjens IMCM
Arch Toxicol; 2017 Sep; 91(9):3093-3108. PubMed ID: 28357488
[TBL] [Abstract][Full Text] [Related]
19. A trichloroethylene risk assessment using a Monte Carlo analysis of parameter uncertainty in conjunction with physiologically-based pharmacokinetic modeling.
Cronin WJ; Oswald EJ; Shelley ML; Fisher JW; Flemming CD
Risk Anal; 1995 Oct; 15(5):555-65. PubMed ID: 7501875
[TBL] [Abstract][Full Text] [Related]
20. Separating uncertainty and physiological variability in human PBPK modelling: The example of 2-propanol and its metabolite acetone.
Huizer D; Oldenkamp R; Ragas AM; van Rooij JG; Huijbregts MA
Toxicol Lett; 2012 Oct; 214(2):154-65. PubMed ID: 22955064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
